SEC Form 4 · accession 0001209191-17-035187
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren P Silvernail
Officer — CFO, CBO & Secretary
Period of report
May 22, 2017
Accepted (ET)
May 24, 2017 · 9:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | May 22, 2017 | S | 1,793 | $20.1964 | D | 36,566 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to an irrevocable sell to cover election previously adopted by Mrs. Silvernail.
- F2The shares were disposed to satisfy tax withholding obligations that arose in connection with the vesting of 4,667 shares of restricted stock on May 19, 2017.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.20. Mrs. Silvernail undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.